Physician profile

Michael E Fox

Pulmonary Disease · Orange, CA

NPI 1053389254

$1,896.68

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $419.75 2019-2020
Astrazeneca Pharmaceuticals Lp $230.54 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $219.13 2019-2021
Janssen Pharmaceuticals, INC $132.09 2019-2020
Allergan, INC. $90.68 2019-2020
Vanda Pharmaceuticals INC. $89.97 2020
Insmed, INC. $89.83 2019-2021
Lilly USA, LLC $75.04 2020-2021
Pfizer INC. $67.78 2019
Abbvie INC. $64.14 2020
Genentech USA, INC. $59.88 2019
Actelion Pharmaceuticals US, INC. $56.23 2019-2021
Grifols USA, LLC $37.53 2020
Merck Sharp & Dohme LLC $37.29 2019-2020
Mylan Specialty L.P. $32.81 2019
Show all 25 companies
CompanyGeneral paymentsYearsTop products
Mayne Pharma Commercial LLC $31.35 2020
Philips North America LLC $24.64 2020
Tactile Systems Technology INC $23.69 2019-2020
Medtronic, INC. $23.65 2022
Novo Nordisk INC $19.00 2021
Novartis Pharmaceuticals Corporation $17.84 2019
E.R. Squibb & Sons, L.L.C. $14.43 2021
Vertiflex, INC. $14.00 2019
Sanofi Pasteur INC. $13.09 2019
Teva Pharmaceuticals USA, INC. $12.30 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael E Fox

$1,896.68

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/138177/michael-e-fox

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.